Evaluation of Blood Flow Characteristics in Glaucoma Using Optical Coherence Tomography Angiography (OCT-A).

Glaucoma Clinical Trial

Official title:

A Cross-sectional, Prospective, Observational Study to Evaluate Blood Flow Characteristics in Glaucoma Patients Using Optical Coherence Tomography Based Angiography (OCT-A).

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02757677
• Other study ID #: GR-02
• Status: Terminated
• Start date: December 31, 2015
• Est. completion date: December 31, 2019

Study information

• Verified date: May 2022
• Source: Swiss Vision Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators aim to evaluate the efficacy of the new Optical Coherence Tomography based Angiography (OCT-A) softwares in the diagnosis and management of glaucoma.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 200
• Est. completion date: December 31, 2019
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of open angle glaucoma (OAG) including pseudo-exfoliative and pigmentary glaucoma.

• Documented glaucomatous visual field damage (in the previous 12 months with mean defect (MD) > 2.0 dB)

• Structural and/or functional glaucomatous damage

• Have given written informed consent, prior to any investigational procedures

Exclusion Criteria:

• Patients with allergy to corneal anesthetic

• Patients not able to understand the character and individual consequences of the investigation

• Participation in other clinical research within the last 4 weeks

• Other diseases that may cause visual field loss or optic disc abnormalities

• Refractive error of > +3.00D or < -7.00D

Related Conditions & MeSH terms

• Glaucoma

Intervention

Device:
• Optical Coherence Tomography based Angiography
A contrast-free, noninvasive technology to identify blood vessels in the eye

Locations

Country	Name	City	State
Switzerland	Glaucoma center, Montchoisi clinic	Lausanne

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Vision Network

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Macular and optic nerve head bloodflow, as measured by OCT-A macular and optic nerve head vessel density (%)		Up to 3 years